Steric Inhibitor Antibody Allergen Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergic responses, particularly food allergies, are limited in effectively preventing anaphylaxis and improving quality of life due to the hypersensitivity of the immune system to harmless substances, leading to severe reactions and lifelong avoidance measures.
Innovation Solution
Therapeutic compositions comprising antibodies or antibody fragments coupled with a steric inhibitor that bind to allergens, preventing IgE-mediated cross-linking and degranulation of mast cells and basophils by sterically blocking further antigen binding, thereby inhibiting allergic reactions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional allergy treatments are used, then patients can manage mild symptoms, but they cannot effectively prevent anaphylaxis and must practice strict lifelong avoidance
Solution Approach 1:
The patent uses an antibody-steric inhibitor complex as an intermediary substance that binds to the allergen and physically blocks IgE antibodies from binding to it. This mediator prevents the harmful interaction between allergen and IgE without requiring complete avoidance of the allergen, thereby effectively preventing anaphylaxis while improving quality of life
Solution Approach 2:
The therapeutic composition is administered before exposure to the allergen to pre-block the binding sites. The antibody-steric inhibitor complex is already in place to prevent IgE-mediated cross-linking before the allergic reaction can initiate, providing preliminary protection against anaphylaxis
2Object-affected harmful factors
If IgE antibodies bind to allergens, then allergic reactions occur through cross-linking and degranulation, but preventing this binding requires blocking the interaction between IgE and allergen epitopes
Solution Approach 1:
The patent employs a composite therapeutic composition consisting of an antibody conjugated to a steric inhibitor. This composite structure combines the high specificity of the antibody for the allergen epitope with the physical blocking capability of the steric inhibitor, achieving effective prevention of IgE binding while managing the complexity through a well-defined molecular architecture
Solution Approach 2:
The therapeutic composition is segmented into two functional components: the antibody portion that provides specific recognition and binding to the allergen epitope, and the steric inhibitor portion that provides physical blockage. This segmentation allows each component to perform its specialized function while together they prevent the harmful allergic reaction
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions effectively prevent IgE-mediated cross-linking and degranulation, reducing the risk of anaphylaxis and alleviating allergic responses, offering a potential solution for managing various types of allergies by blocking allergen binding to IgE receptors on mast cells and basophils.
Implementation Method 1
an antibody or antigen-binding fragment thereof that specifically binds an epitope on an allergen
Implementation Method 2
includes a steric inhibitor coupled to the antibody or antigen-binding fragment that prevents IgE-mediated cross-linking and degranulation
Data Source
AI summary
The invention generally relates to therapeutic methods for treating and suppressing allergic responses. The invention provides therapeutic compositions and methods for treating and suppressing allergic responses using antibodies, antibody fragments thereof, or other products of the immune system coupled with a steric inhibitor to bind to an epitope on an allergen. Because of the steric inhibitor, the composition prevents one or more IgE antibodies from binding to the allergen. By blocking one or more IgE antibodies from binding to the allergen, the composition prevents IgE-mediated cross-linking and degranulation of mast cells and basophils, thus inhibiting anaphylaxis.